OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Jkdground breaking news!

http://www.oxfordbiomedica.co.uk/userfiles/file/pdfs/OBM0111JPM.pdf

Market chatter suggests gene-therapy company Oxford BioMedica (OXB)
is very close to closing a deal to purchase a UK manufacturing facility so it can establish in-house drug production. Buy ahead of the deal being confirmed. Oxford wants its own capacity as it has five other products in clinical development, including a cancer vaccine, Trovax, in Phase II trials. (CM)
Shares says: Speculative Buy at 5.5p

I read that rumour too, (was it you?), but I'm not convinced, unless there is a facility on the cheap.... for they need the Rights money and would have have to have told subscribers/shareholders what they were doing...as that was a while ago (yep!) I think this cash is for working capital...that was what we were told...(anyone?).

Still, often wrong, it would make sense to buy a small Bio-dev.Co. that needed their contacts. Whereas I don't think OXB needs a manufacturing facility - I understood they had some Trovax made a while back and this is still in the fridge. Trials-volume req'd isn't enough to start a production. However, if they can secure a bread-n-butter product, that changes everything.
+ I bought a few more at these lows....but I'm wary we've been seeing lows . . . . . . for rather too long.

HangonI wrote to the company some time ago concerning the manufacturing facilityalong with some other questions

This is part of the reply I received from Lara


"Dear *******


Regarding the manufacturing point you have raised below, we have an exclusive option to acquire a UK-based manufacturing facility at a fraction of the cost of a new-build. We currently have one Phase I/II product, ProSavin, which utilises our EIAV-based LentiVector technology platform (EIAV stands for our equine infectious anemia virus which we use to deliver the genes), however we have four LentiVector-based ocular products, partnered with sanofi-aventis, moving into clinical development over the next 18 months. This moves us from one LentiVector-based programme to five clinically active programmes.

We estimate that it will take about 12 months to bring the manufacturing unit on-stream, but thereafter, based on present plans, the amount of clinical-grade material that our development programmes will require could make the manufacturing unit cost-effective. With five LentiVector products moving from Ph I/II through to Ph II, Ph III and the market, we plan to support our five programmes with control of supply and we would eventually also have the opportunity to be the preferred supplier for our commercial partners.

I hope this provides some clarity.

Best wishes,
Lara"

I now believe OXB are developing the business on privileged information and assurances from partnersthe 18.4ml netwill fund ProSavininvest in manufacturing infrastructure for the LentiVector programmesstrengthen the balance sheetwhich will give OXB a stronger negotiating position for partnering dealsand take us way past the first catalysts associated with the ocular assetsthere is also double digit million dollar milestone paymentswhen Sanofi exercise one or more of the ocular programmesall in all hangonwe now look pretty damn strong

kiss of death!

We have had all the bad news pricedI will be very surprised if the SP is not considerably higher come this date!

Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), today announces that it will be releasing its preliminary results for the twelve months ended 31 December 2010 on Wednesday 2 March 2011.
An analyst briefing will be held at 9:30am GMT on Wednesday 2 March 2011 at the offices of M:Communications, CityPoint, 1 Ropemaker Street, London, EC2Y 9AW.
Simultaneously to the analyst briefing at 9:30am GMT, there will be a live audio webcast of the presentation. To connect to the webcast facility, please visit the Company's website: www.oxfordbiomedica.co.uk approximately 10 minutes (9:20am GMT) before the start of the briefing. A replay will be made available shortly after the presentation.

If you read between the lines OXBs statement on the 22nd December 2010 looks pretty bullishfast track 5x dosethe start of 5x dose treatment is timed perfectly with the preliminary results in MarchDMC approval to open the second site in the UK at Addenbrookesa Phase II trial of ProSavin could be initiated in the EU/US in 2012 and planning is underway for this stage of the development programmeand all around the very badly timed fundraising?Looks fairly confident action to me!

The study's independent Data Monitoring Committee (DMC) has reviewed the data and supports the Company's proposal to proceed to a 5x dose, facilitated by the enhanced administration technique, in a six-patient cohort. Importantly, the 5x human dose is the allometrically-scaled equivalent (i.e. a dose that is scaled for the difference in brain size between humans and the pre-clinical model) to the highly efficacious pre-clinical dose published in Jarraya et al. Sci Transl Med. 2009 Oct 14;1(2). The DMC also gave its approval to open the second site in the UK at Addenbrookes Hospital, Cambridge, with Dr Roger Barker as Principal Investigator, which will recruit some of the six patients into the 5x dose cohort.

Oxford BioMedica plans to initiate treatment of the 5x dose cohort in Q1 2011. To date, nine patients have been treated at the Henri Mondor Hospital, Paris, with Professor Sthane Palfi as Principal Investigator. The first patient in the 5x dose cohort will be treated in Paris, one month after which subsequent patients can be treated in parallel at both sites which is expected to increase the rate of recruitment and treatment. Results from the first three patients in the 5x dose cohort are expected in mid-2011. Depending on the efficacy seen with the 5x dose, a Phase II trial of ProSavin could be initiated in the EU/US in 2012 and planning is underway for this stage of the development programme.

http://clinicaltrials.gov/ct2/show/NCT00627588?term=prosavin&rank=1

ProSavin still at least 3 years away from production, assuming it gets through Phase II and III.

OXB will either have been taken over by then or have returned to the market for additional funds many times over. Very rarely do tiny Bios ever progress a drug from inception to the shelves.

On occasion the market gets excited about the possibilities of a new drug with a likewise reaction to the SP. AZM were a good example, but still ended up in administration.

Blimey - didn't realise this lot were still around.

cor! what a stinkerooney of a chart ...... i know Toya (of blessed memory) used to follow this carefully ..... i wonder what has become of her?

i sold outta oxb and pym about a year ago at around the same time, not really kept up much just occasional glance at oxb because of how long pharma approvals can take - i need to te view pym also - when i sold it was around the time michael fox foundation was providing some research cash - anyhow sp here looks interesting here now - knew about the potential manufacturing side some time ago but heard that the site and facilities will not be that good more a non preferred cheap option so tended to keep away - anything imminent here or no more than 6 mths away to get excited about - was nearly locked in here once & pym till the 10p / share offer allowed me to recoup losses - just looked up posts above & see pth makes some relevant points and tabasco also - looks like my 6mth hope out the window then - and yep chart none too hot - gla

by the way the mj fox research cash comment last post was ref pym not oxb

Little time to post this weekin Norfolk/Suffolkand have a lot to dobut couldnt miss this biggiecheap as chips!


Acquisition of Manufacturing Facility
Share this article
TIDMOXB

RNS Number : 2988A

Oxford Biomedica PLC

31 January 2011

OXFORD BIOMEDICA ACQUIRES GMP MANUFACTURING FACILITY

-- Support for Oxford BioMedica's five LentiVector(R) technology-based programmes --

-- UK production facility in Oxford to be operational in 2012 --

Oxford, UK - 31 January 2011: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, today announces that it has agreed to acquire a manufacturing facility ("the facility") based in Oxford, UK from RecipharmCobra Biologics, the specialist biologics division of Recipharm AB, for a purchase price of GBP1.9 million.

The acquisition and operation of this manufacturing facility is a planned use of proceeds following the Company's recent GBP20 million fundraising which closed on 10 January 2011. The acquisition of the facility is expected to complete by the end of February 2011.

The manufacturing facility will enable Oxford BioMedica to have greater control of the production of its proprietary LentiVector(R) gene delivery technology in order to support five of the Company's clinical programmes. With the ocular products partnered with sanofi-aventis advancing into Phase I/II development during 2011, in addition to the planned progression of ProSavin(R) into a randomised Phase II study for Parkinson's disease in 2012, the facility is expected to deliver long-term operational and financial efficiencies for the Company in comparison to outsourcing processes to a specialist contract manufacturing organisation. This acquisition will also reduce the Company's dependence on a single manufacturing source for its growing clinical portfolio and facilitate the rapid implementation of improved manufacturing processes at increased scale.

The facility totals approximately 16,000 square feet, which includes c. 4,400 square feet in cleanrooms, and is already configured to meet the Company's manufacturing requirements. The facility was previously approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to Good Manufacturing Practice (GMP) standards. Oxford BioMedica anticipates a minimum of 12 months to re-commission the facility which will include the first phase of staff recruitment towards the anticipated fully-operational level of about 35 to 40 staff. The Company estimates an annual running cost of approximately GBP2.2 million per annum for the facility.

John Dawson, Chief Executive Officer of Oxford BioMedica, said: "As our ocular programme continues to advance we look forward to the significant growth of our clinical portfolio from two lead products, ProSavin(R) for Parkinson's disease and RetinoStat(R) for "wet" AMD, to five clinical products using our proprietary LentiVector(R) gene delivery technology. Investment in our specialist manufacturing processes will ensure the rapid progression of these five products through Phase II, Phase III and to market. Importantly, this acquisition also provides the opportunity for Oxford BioMedica to become the LentiVector(R) technology supplier of choice for its current and future partners which could provide additional revenues in the coming years."

-Ends-

gibby - PYM is having its agm in London, soon. Will you attend? FWIW I suspect they want more money, hence attracting City types to the AGM (usually the arer in Godmanchester and only the Registrar travels there! HUh).

OXB- SP is taking a time to recover...any ideas? Volumes of Sell outweigh Buys (today 7:1)- ooer that's looking pretty poor.

tabasco - I'm guessing you are reasonably bullish, any comment on current sp? - and did OXB tell us about that Mfr option?
I just don't believe they need it - yet as a LT deal it makes sense, but I don't know what capacity this facility has* - or IF it needs more cash to get it on-line. Was it a good-deal I wonder?
The SP is telling otherwise...

PYM (ditto,) ==pair of smelly eggs - but which is rotten?



*but yr post 31Jan helps.

Hangonthis might help.

http://www.oxfordtimes.co.uk/business/8828490.BioMedica_buys_mothballed_plant/

With OXB eventually recruiting another 35-40 high-tech jobs for their manufacturing plantthey must be extremely confident covering that additional huge costor know more than they are saying? my guess is Sanofi-Aventis have made some guarantees?I believe SA have a trading update next week
This stock is definitely a puntbut I fancy the odds strongly at this 5-6p levelmight prove to be very tastywith a bit of luck?

tabasco - thanks for the link, I wondered this wasn't the old [AIM-]Cobra-plant (now gone away)...got out of that stinker, but their plant is fairly modern I guess.

tabasco, - er, why sanofi? They departed PDQ a while ago and gave OXB 14m (was it?), which I assume has been spent wisely...already.

I'm wondering if OXB has sent a few profs down to Sandwich, where Phizer is shutting shop. Far too expensive to "take-over" but there are bound to be a few who would be prepared to move to Oxford.

That Phizer plant was responsible for Viagra, which is soon off-patent... but some similar research is needed for OXB as I am concerned this Cancer-Co is taking too long to turn any profit....we don't need ideals - - - - - we need "product-sales" and nothing so far.

This puts OXB in the same sad-basket as PYM...who have yet to sell one tin of weight-reduction.......Grr.

Tabasco: thanks for that link to the Oxford Times.

I did hear good things about OXB and ASM while working in Oxford a couple of years back. And yes Cynic: I did used to trade both these but got out of them a long time ago. I'm not tempted to risk any more funds on small biotechs and agree with ptholden that they are very risky businesses. Some do pull through, of course, but there are better places to go fishing I reckon.

Cheers Toya

They are not wasting a lot of time here then?

Oxford Biomedica PLC

09 February 2011

OXFORD BIOMEDICA APPOINTS JAMES CHRISTIE AS NEW HEAD OF MANUFACTURING

with immediate effect.

Just wonder if OXB are being held down by mm's in order for people to close their shortssome large sells going through

CMC
UK AIM Share Bets AIM share bets that remain open will be closed out at the closing price on 11 February 2011